| 000 | 01586 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250517092009.0 | ||
| 264 | 0 | _c20170127 | |
| 008 | 201701s 0 0 eng d | ||
| 022 | _a1432-0584 | ||
| 024 | 7 |
_a10.1007/s00277-016-2670-6 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGhanizadeh-Vesali, Samad | |
| 245 | 0 | 0 |
_aSignificance of AZD1152 as a potential treatment against Aurora B overexpression in acute promyelocytic leukemia. _h[electronic resource] |
| 260 |
_bAnnals of hematology _cJun 2016 |
||
| 300 |
_a1031-42 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAurora Kinase B _xantagonists & inhibitors |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aCell Proliferation _xdrug effects |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGene Expression Regulation, Neoplastic |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLeukemia, Promyelocytic, Acute _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aOrganophosphates _xpharmacology |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aQuinazolines _xpharmacology |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aZekri, Ali | |
| 700 | 1 | _aZaker, Farhad | |
| 700 | 1 | _aZaghal, Azam | |
| 700 | 1 | _aYousefi, Meysam | |
| 700 | 1 | _aAlimoghaddam, Kamran | |
| 700 | 1 | _aGhavamzadeh, Ardeshir | |
| 700 | 1 | _aGhaffari, Seyed H | |
| 773 | 0 |
_tAnnals of hematology _gvol. 95 _gno. 7 _gp. 1031-42 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00277-016-2670-6 _zAvailable from publisher's website |
| 999 |
_c25937610 _d25937610 |
||